Details:
Partnership brings together Vifor Pharma’s world-class iron deficiency portfolio with Fresenius Kabi’s market-leading patient access in China.
Lead Product(s): Ferric Carboxymaltose
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: CSL Vifor
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 20, 2020